Physician profile
Prem Sobti
NPI 1932159993
$1,868.20
in general payments reported to CMS, 2019-2025
30 companies · $136 in 2025
The $136 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,063 · 2020: $297 · 2021: $179 · 2022: $122 · 2023: $15.72 · 2024: $54.41 · 2025: $136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $192 · Education: $14.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $192.39 |
| Education | $14.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $316.67 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $205.83 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $127.72 | 2019-2020 | |
| Amgen INC. | $126.26 | 2019 | |
| Celgene Corporation | $114.37 | 2019-2020 | |
| Genentech USA, INC. | $97.27 | 2019 | |
| Pfizer INC. | $88.56 | 2019-2025 | |
| Janssen Biotech, INC. | $88.13 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $75.99 | 2019 | |
| Daiichi Sankyo INC. | $61.77 | 2019-2025 | Enhertu |
| Emd Serono, INC. | $59.85 | 2019-2025 | |
| Seagen INC. | $53.78 | 2020 | |
| Genzyme Corporation | $53.29 | 2019-2020 | |
| Array Biopharma INC | $45.36 | 2020-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.51 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $33.62 | 2019-2025 | Vyloy |
| Bayer Healthcare Pharmaceuticals INC. | $32.61 | 2019-2020 | |
| Eisai INC. | $32.50 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $31.81 | 2019 | |
| Exelixis INC. | $31.47 | 2019 | |
| Incyte Corporation | $27.30 | 2019 | |
| Gilead Sciences, INC. | $24.84 | 2025 | Trodelvy |
| Genentech, INC. | $21.42 | 2024 | Columvi, Alecensa, Avastin |
| Abbvie INC. | $15.02 | 2025 | |
| Coherus Oncology, INC. | $14.41 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $14.38 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.29 | 2019 | |
| Rigel Pharmaceuticals, INC. | $12.26 | 2019 | |
| Clovis Oncology, INC. | $9.91 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prem Sobti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.